Company Information
TFF was founded on January 2018. The company is based in Austin, TX, USA . The number of employees in TFF is less than 10. Tff is an early-stage biopharmaceutical company.Funding & investors
TFF has received 3 rounds of venture funding. The total funding amount is around $48.2M. Last venture funding round was $25.9M, announced on August, 2020.- Liquid Ventures (Venture capital)
Similar Companies [beta]
- Relay therapeutics
- Antolrx
- Rapt therapeutics
- Neuraptive therapeutics
- Checkmate pharmaceuticals
- Repare therapeutics
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
News
TFF - Blog
- TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments
- TFF Pharmaceuticals Receives Notice of Intention to Grant European Patent for Its Thin Film Freezing Process, Providing IP Protection in Europe until 2028
- TFF Pharmaceuticals Receives Notice of Allowance for New Foundational Patent Broadly Covering Novel Inhaled Dry Powder Drug Delivery Platform
- TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
- Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
AUSTIN, TX (BusinessWire)– May 29, 2019 — TFF Pharmaceuticals, Inc. (TFF), an early-stage biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of chronic respiratory diseases and lung conditions, today announced it has closed an $8.17 million offering of Series A Preferred Stock. The proceeds from this transaction will provide … Read more
AUSTIN, Texas–(BUSINESS WIRE)–TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of chronic respiratory diseases and lung conditions, today announced having received a European Patent Office (EPO) Notice of Intent to Grant Patent Application No. 08771657.7, “Formation of Stable Submicron Peptide or Protein Particles by … Read more
AUSTIN, Texas, July 11, 2018 /PRNewswire/ — TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, announced today the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/778,795, “Compositions and Methods of Making … Read more
AUSTIN, Texas, May 8, 2018 /PRNewswire/ — TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, announced today it has named Glenn Mattes as Chief Executive Officer of the Company. Mr. Mattes brings over thirty years of successful business and industry … Read more
The Series A financing will support further development of the Company’s pipeline of transformative dry powder drugs for pulmonary diseases and conditions.AUSTIN, TX, April 3, 2018/PR Newswire – TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, announced it has closed … Read more
Share:
